Perrigo (NYSE:PRGO) received a $100.00 price target from Canaccord Genuity in a report issued on Tuesday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 14.73% from the stock’s previous close.
PRGO has been the subject of a number of other reports. Barclays increased their price target on shares of Perrigo to $93.00 and gave the stock an “overweight” rating in a research note on Monday, December 4th. Royal Bank of Canada reissued a “sell” rating and issued a $64.00 price target on shares of Perrigo in a research note on Wednesday, September 13th. Deutsche Bank increased their price target on shares of Perrigo from $88.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, September 14th. Oppenheimer started coverage on shares of Perrigo in a research note on Monday, October 2nd. They set a “buy” rating and a $88.00 target price for the company. Finally, Wells Fargo & Co raised their target price on shares of Perrigo to $90.00 and gave the company a “market perform” rating in a research note on Friday, November 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $92.13.
Perrigo (PRGO) traded down $0.13 during trading on Tuesday, hitting $87.16. 442,315 shares of the stock were exchanged, compared to its average volume of 1,010,000. The company has a current ratio of 1.72, a quick ratio of 1.24 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $12,290.00, a price-to-earnings ratio of -9.52, a P/E/G ratio of 1.88 and a beta of 0.64. Perrigo has a one year low of $63.68 and a one year high of $91.73.
In other Perrigo news, EVP John Wesolowski sold 388 shares of Perrigo stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $87.20, for a total value of $33,833.60. Following the sale, the executive vice president now directly owns 248 shares in the company, valued at approximately $21,625.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Todd W. Kingma sold 1,500 shares of Perrigo stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $88.52, for a total transaction of $132,780.00. Following the completion of the sale, the vice president now owns 19,565 shares in the company, valued at $1,731,893.80. The disclosure for this sale can be found here. Insiders have sold a total of 2,551 shares of company stock worth $222,590 over the last 90 days. Insiders own 6.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Parametric Portfolio Associates LLC increased its holdings in Perrigo by 29.6% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 229,115 shares of the company’s stock valued at $19,395,000 after acquiring an additional 52,361 shares during the last quarter. Greenlight Capital Inc. increased its holdings in shares of Perrigo by 14.8% in the 3rd quarter. Greenlight Capital Inc. now owns 2,901,032 shares of the company’s stock worth $245,572,000 after buying an additional 374,032 shares during the last quarter. Cetera Advisors LLC bought a new stake in shares of Perrigo in the 3rd quarter worth about $398,000. California Public Employees Retirement System increased its holdings in shares of Perrigo by 3.9% in the 3rd quarter. California Public Employees Retirement System now owns 284,066 shares of the company’s stock worth $24,046,000 after buying an additional 10,766 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Perrigo in the 3rd quarter worth about $12,706,000. Institutional investors own 83.29% of the company’s stock.
WARNING: “Canaccord Genuity Analysts Give Perrigo (PRGO) a $100.00 Price Target” was originally reported by American Market News and is the property of of American Market News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/29/canaccord-genuity-analysts-give-perrigo-prgo-a-100-00-price-target.html.
About Perrigo
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
